A field evaluation of a new porcine circovirus type 2d and Mycoplasma hyopneumoniae bivalent vaccine in herds suffering from subclinical PCV2d infection and enzootic pneumonia
Veterinary Medicine and Science · 2024
DOI: 10.1002/vms3.70001 ↗At a glance
Journal article in Veterinary Medicine and Science, 2024. Written by Sehyeong Ham and 5 co-authors. Institution: Department of Veterinary Pathology, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea. Major MEDLINE topics: Circovirus, Mycoplasma hyopneumoniae, Circoviridae Infections, Pneumonia of Swine, Mycoplasmal. Cited 3 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY 4.0). Funded by: Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry.
Abstract (original language)
Background
This field efficacy study was designed to determine the efficacy of a new bivalent vaccine containing porcine circovirus type 2d (PCV2d) and Mycoplasma hyopneumoniae at three independent pig farms.
Methods
Three pig farms were selected based on their history of subclinical PCV2 infection and enzootic pneumonia. Each farm housed a total of 40, 18‐day‐old pigs that were randomly allocated to 1 of 2 treatment groups. Pigs were administered a 2.0 mL dose of the bivalent vaccine intramuscularly at 21 days of age in accordance with the manufacturer's recommendations, whereas unvaccinated pigs were administered a single dose of phosphate‐buffered saline at the same age.
Results
Clinically, the average daily weight gain of vaccinated groups was significantly higher ( p < 0.05) than those of unvaccinated animals during the growing (70–112 days of age), finishing (112–175 days of age) and overall (3–175 days of age) stages of production. Vaccinated animals elicited neutralizing anti‐PCV2 antibodies and PCV2d‐specific interferon‐γ secreting cells (IFN‐γ‐SC), which reduced the amount of PCV2d genomic copies in blood and reduced lymphoid lesions severity when compared with unvaccinated animals. Similarly, vaccinated animals elicited M. hyopneumoniae ‐specific IFN‐γ‐SC, which reduced the amount of M. hyopneumoniae in the larynx and reduced lung lesions severity.
Conclusions
The result of the field trial demonstrated that the bivalent vaccine was efficacious in the protection of swine herds suffering from subclinical PCV2d infection and enzootic pneumonia.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Veterinary Pathology, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea.
- WOOGENE B&G CO., LTD., Seoul, Republic of Korea.
ORCID profiles: Sehyeong Ham, Jeongmin Suh, Chanhee Chae
Funding
- Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry
Cite
APA
Ham, S., Suh, J., Kim, C., Seo, B. J., Park, G. S., & Chae, C. (2024). A field evaluation of a new porcine circovirus type 2d and Mycoplasma hyopneumoniae bivalent vaccine in herds suffering from subclinical PCV2d infection and enzootic pneumonia. Veterinary Medicine and Science. https://doi.org/10.1002/vms3.70001
Vancouver
Ham S, Suh J, Kim C, Seo BJ, Park GS, Chae C. A field evaluation of a new porcine circovirus type 2d and Mycoplasma hyopneumoniae bivalent vaccine in herds suffering from subclinical PCV2d infection and enzootic pneumonia. Veterinary Medicine and Science. 2024. doi:10.1002/vms3.70001
BibTeX
@article{Ham2024,
author = {Ham, Sehyeong and Suh, Jeongmin and Kim, Chonghan and Seo, Byoung-Joo and Park, Gyeong-Seo and Chae, Chanhee},
title = {A field evaluation of a new porcine circovirus type 2d and Mycoplasma hyopneumoniae bivalent vaccine in herds suffering from subclinical PCV2d infection and enzootic pneumonia},
journal = {Veterinary Medicine and Science},
year = {2024},
doi = {10.1002/vms3.70001}
}
EUVIMED